Myelofibrosis clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with advanced cancers who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT543.
San Francisco, California and other locations
Our lead scientists for Myelofibrosis research studies include Hyunseok Kang.